Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat.

Rajendrakumar K, Madhusudan S, Pralhad T

Facile exchange of glycosyl S,S-acetals to their O,O-acetals and preparation of glycofuranosides from acyclic glycosyl S,S-acetals under metal-free reaction conditions in the presence of 1,3-dibromo-5,5-dimethylhydantoin.

Madhusudan SK, Misra AK

Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.

Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, White L, Kan O, Naylor S, Carroll MW, Kingsman SM, Harris AL

HClO4-SiO2 catalyzed per-O-acetylation of carbohydrates.

Misra AK, Tiwari P, Madhusudan SK

Effect of metal cationization on the tandem mass spectra of glycosyl dithioacetals.

Madhusudanan KP, Kumar B, Tiwari P, Madhusudan SK, Misra AK

Tandem mass spectra of transition-metal ion adducts of glycosyl dithioacetals; distinction among stereoisomers.

Madhusudanan KP, Kumar B, Tiwari P, Madhusudan SK, Misra AK

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.

Deplanque G, Madhusudan S, Jones PH, Wellmann S, Christodoulos K, Talbot DC, Ganesan TS, Blann A, Harris AL

A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL

Tyrosine kinase inhibitors in cancer therapy.

Madhusudan S, Ganesan TS

A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene.

Madhusudan S, Tamir A, Bates N, Flanagan E, Gore ME, Barton DP, Harper P, Seckl M, Thomas H, Lemoine NR, Charnock M, Habib NA, Lechler R, Nicholls J, Pignatelli M, Ganesan TS

Antiangiogenic therapy for von Hippel-Lindau disease.

Madhusudan S, Deplanque G, Braybrooke JP, Cattell E, Taylor M, Price P, Tsaloumas MD, Moore N, Huson SM, Adams C, Frith P, Scigalla P, Harris AL

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.

Madhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P, Turner A, Balkwill F, Hoare S, Harris AL

Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.

Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, Wilner S, Harris AL, Talbot DC

Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases.

Pralhad T, Madhusudan S, Rajendrakumar K

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL